Global Psychedelic Drugs Market Expected To Reach $10.2B By 2028 Amid Growing Mental Health Crises
Global Psychedelic Drugs Market Expected To Reach $10.2B By 2028 Amid Growing Mental Health Crises
The market includes various types of psychedelics categorized by drug (LSD, ketamine, GHB), indication (depression, PTSD) and origin (natural or synthetic). Applications range from treatment-resistant depression to panic disorders, with distribution spanning hospitals, retail and online pharmacies.The global psychedelic drugs market is set for rapid expansion, with projections forecasting growth from $4.88 billion in 2023 to $10.2 billion by 2028, according to The Business Research Company. With a compound annual growth rate of 16.1%, this rise is largely driven by increased awareness of mental health needs, progressive regulatory shifts and the medical community's growing acceptance of psychedelics for therapeutic applications.
全球迷幻藥品市場即將迎來快速擴張，根據商業研究公司的預測，從2023年的48.8億美元增長到2028年的102億美元。這一增長主要受益於對心理健康需求增加的認識、進步的監管轉變以及醫療社區對用於治療的迷幻藥物日益接受。複合年增長率達到16.1%的這種增長主要受益於對心理健康需求增加的認識、進步的監管轉變以及醫療社區對用於治療的迷幻藥物日益接受。
Key Market Drivers: Mental Health Awareness And Regulatory Changes
關鍵市場驅動因素：心理健康意識和監管變化
The surge in mental health disorders, including treatment-resistant depression and PTSD, is fueling demand for alternative treatments like psychedelics. "Psychedelic drugs are utilized for treating depression and PTSD, contributing to a decrease in mental health issues," notes The Business Research Company. Psychedelics such as LSD, ketamine, and newer innovations like depression-targeting nasal sprays are becoming prominent options for patients and providers alike.
心理健康障礙的激增，包括治療抵抗性抑鬱症和創傷後應激障礙(PTSD)，推動了迷幻藥品等替代療法的需求增長。商業研究公司指出:"迷幻藥物用於治療抑鬱症和創傷後應激障礙，有助於減少心理健康問題"。LSD、氯胺酮、以及如針對抑鬱症的噴鼻藥等創新逐漸成爲患者和醫療服務提供者的主要選擇。
Trends Shaping The Psychedelic Drugs Market
塑造迷幻藥品市場的趨勢
Key trends include a focus on public education, regulatory adaptation, and diversification of compounds. Companies such as Pfizer (NYSE:PFE), Johnson & Johnson (NYSE:JNJ) and Mydecine Innovations Group (OTC:MYCOF) are actively advancing in this sector to develop treatments that cater to evolving patient needs. North America currently leads the market, with Asia-Pacific expected to see the fastest growth through 2033 due to increasing policy changes and investment in mental health infrastructure.
關鍵趨勢包括公衆教育、監管適應以及藥物多樣化。輝瑞(紐交所:PFE)、強生(紐交所:JNJ)和Mydecine Innovations Group(場外交易:MYCOF)等公司正在積極推動該領域的發展，以研發能夠滿足不斷髮展的患者需求的治療方案。目前北美表現爲市場的領頭羊，預計到2033年，亞太地區將由於政策變化和對心理健康基礎設施的投資而實現最快增長。
Market Segmentation: Psychedelic Compounds And Indications
市場細分：迷幻複合物與適應症
The market includes various types of psychedelics categorized by drug (LSD, ketamine, GHB), indication (depression, PTSD) and origin (natural or synthetic). Applications range from treatment-resistant depression to panic disorders, with distribution spanning hospitals, retail and online pharmacies.
市場包括不同類型的迷幻藥物，按藥物(LSD、氯胺酮、GHB)、適應症(抑鬱症、PTSD)和來源(天然或合成)分類。應用範圍從治療抵抗性抑鬱症到驚恐障礙，分佈範圍涵蓋醫院、零售店和在線藥房。
Outlook And Opportunities For Psychedelic Drug Developers
迷幻藥物開發者的展望和機遇
As research continues to support psychedelics' benefits in mental health treatment, companies are poised to capitalize on both emerging treatment areas and regional growth opportunities. With major pharmaceutical players investing in these compounds, the market is expected to become increasingly competitive and patient-focused, highlighting a promising outlook for psychedelic treatments.
隨着研究不斷支持致幻劑在心理健康治療中的益處，企業將能夠充分利用新興治療領域和區域增長機會。隨着主要藥品生產商投資於這些化合物，市場預計將變得日益競爭激烈且以患者爲中心，爲致幻療法展現了一個充滿希望的前景。
Cover image made with AI
封面圖片由人工智能製作
譯文內容由第三人軟體翻譯。
